Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...

We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...

InTandem Capital Partners (“InTandem Capital” or the “Firm”), a healthcare services-focused private equity firm, announced today that it has partnered with ...

"In contrast, very few neurons in the central nervous system itself expressed Cdkl ... Borja, Stephanie Bivona, Undiagnosed Diseases Network, Baylor College of Medicine Center for Precision ...